705 related articles for article (PubMed ID: 15142631)
1. Review of epidermal growth factor receptor biology.
Herbst RS
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):21-6. PubMed ID: 15142631
[TBL] [Abstract][Full Text] [Related]
2. Epidermal growth factor receptor inhibition strategies in oncology.
Harari PM
Endocr Relat Cancer; 2004 Dec; 11(4):689-708. PubMed ID: 15613446
[TBL] [Abstract][Full Text] [Related]
3. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
4. [Targeting of epidermal growth factor receptor and applications in ORL cancer].
Tortochaux J; Aunoble B; Rolhion C; Bourhis J
Bull Cancer; 2003 Nov; 90 Spec No():S220-7. PubMed ID: 14763143
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor receptor as a target for colorectal cancer therapy.
Lockhart AC; Berlin JD
Semin Oncol; 2005 Feb; 32(1):52-60. PubMed ID: 15726506
[TBL] [Abstract][Full Text] [Related]
6. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
[TBL] [Abstract][Full Text] [Related]
7. [EGFR/HER1: a target life].
Viel E; Curtit E; Mansi L; Vignot S
Bull Cancer; 2012 Feb; 99(2):181-9. PubMed ID: 21684835
[TBL] [Abstract][Full Text] [Related]
8. Cellular responses to EGFR inhibitors and their relevance to cancer therapy.
Dutta PR; Maity A
Cancer Lett; 2007 Sep; 254(2):165-77. PubMed ID: 17367921
[TBL] [Abstract][Full Text] [Related]
9. [Radiotherapy and inhibitors of epidermal growth factor receptor: preclinical findings and preliminary clinical trials].
Azria D; Larbouret C; Robert B; Culine S; Ychou M; Verrelle P; Dubois JB; Pèlegrin A
Bull Cancer; 2003 Nov; 90 Spec No():S202-12. PubMed ID: 14763141
[TBL] [Abstract][Full Text] [Related]
10. [The use of targeted therapies in oncology and their impact in the design of clinical trials: epidermal growth factor receptors 1 and 2 as a paradigm].
Dalmases A; Rojo F; Rovira A; Albanell J
Med Clin (Barc); 2013 Aug; 141(4):176-80. PubMed ID: 23809407
[No Abstract] [Full Text] [Related]
11. Epidermal growth factor receptor as a therapeutic target in colorectal cancer.
Cohen RB
Clin Colorectal Cancer; 2003 Feb; 2(4):246-51. PubMed ID: 12620146
[TBL] [Abstract][Full Text] [Related]
12. Therapies directed against epidermal growth factor receptor in aerodigestive carcinomas.
Karamouzis MV; Grandis JR; Argiris A
JAMA; 2007 Jul; 298(1):70-82. PubMed ID: 17609492
[TBL] [Abstract][Full Text] [Related]
13. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer.
Bunn PA; Franklin W
Semin Oncol; 2002 Oct; 29(5 Suppl 14):38-44. PubMed ID: 12422312
[TBL] [Abstract][Full Text] [Related]
14. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands.
Carrión-Salip D; Panosa C; Menendez JA; Puig T; Oliveras G; Pandiella A; De Llorens R; Massaguer A
Int J Oncol; 2012 Sep; 41(3):1128-38. PubMed ID: 22684500
[TBL] [Abstract][Full Text] [Related]
16. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
17. Update on HER-kinase-directed therapy in prostate cancer.
Gross ME; Jo S; Agus DB
Clin Adv Hematol Oncol; 2004 Jan; 2(1):53-6, 64. PubMed ID: 16163160
[TBL] [Abstract][Full Text] [Related]
18. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Ritter CA; Arteaga CL
Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
[TBL] [Abstract][Full Text] [Related]
19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
20. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
